Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF0R5I
|
|||
| Drug Name |
ASP0819
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Fibromyalgia [ICD-11: MG30.01; ICD-10: M79.7; ICD-9: 729.1] | Phase 2 | [1], [2] | |
| Company |
Astellas Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium-activated potassium channel KCa3.1 (KCNN4) | Target Info | Activator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. J Pain Res. 2020 Dec 10;13:3355-3369. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.